ADAR1 Capital Buys More Rallybio Shares as Company Shifts Away from Withdrawing Merger, Hinting at Quiet Confidence in Clinical Pipeline.
ADAR1 Capital’s fresh buy of Rallybio shares signals confidence in its clinical‑stage pipeline and may stabilize the biotech’s volatile stock after a stalled merger withdrawal.
3 minutes to read